Close simulation of acute graft-versus-host disease by interleukin-2 administered after autologous bone marrow transplantation for hematologic malignancy

Bone Marrow Transplantation

Volumn 17, Issue 3, 1996, Pages 351-356

  Massumoto, C ^a   Benyunes, M C ^a,b   Sale, G ^a   Beauchamp, M ^a   York, A ^a   Thompson, J A ^b   Buckner, C D ^a,b   Fefer, A ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Autologous marrow transplantation; GVHD; Interleukin 2

Indexed keywords

ANTINEOPLASTIC AGENT; CORTICOSTEROID; HLA DR ANTIGEN; INTERLEUKIN 2;

ADULT; APHERESIS; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; KERATINOCYTE; LYMPHOKINE ACTIVATED KILLER CELL; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; RECURRENCE RISK; SIMULATION; SKIN BIOPSY; SKIN DISEASE; T LYMPHOCYTE; WHOLE BODY RADIATION;

ACUTE DISEASE; ADULT; BONE MARROW TRANSPLANTATION; EVALUATION STUDIES; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HLA-DR ANTIGENS; HUMANS; INTERLEUKIN-2; LEUKEMIA, MYELOCYTIC, ACUTE; LYMPHOMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SKIN DISEASES; T-LYMPHOCYTES; TRANSPLANTATION, AUTOLOGOUS;

EID: 0029865505     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Foa R. Does interleukin-2 have a role in the management of acute leukemia? J Clin Oncol 1993; 11: 1817-1825.
2. Maraninchi D, Biaise D, Viens P et al. High-dose recombinant interleukin-2 and acute myeloid leukemias in relapse. Blood 1991; 78: 2182-2187.
3. Gisselbrecht C, Maraninchi D, Pico JL et al. Interleukin-2 treatment in lymphoma: a phase II multicenter study. Blood 1994; 83: 2081-2085.
4. Fefer A, Truitt RL, Sullivan KM. Adoptive cellular therapy: graft-vs-tumor responses after bone marrow transplantation. In: DeVita VT, Hellman S and Rosenberg SA (eds). Biologic Therapy of Cancer: Principles and Practice. JB Lippincott Co. Philadelphia, 1991.
5. Weiden P, Flournoy N, Thomas E et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. New Engl J Med 1979; 300: 1068-1073.
6. Rappeport J, Reinherz E. Mihm M et al. Acute graft-versus-host disease in recipients of bone-marrow transplants from identical twin donors. Lancet 1979; 2: 717-720.
7. Hood A, Vogelsang G, Black L et al. Acute graft-vs-host disease: development following autologous and syngeneic bone marrow transplantation. Arch Dermatol 1987; 123: 745-750.
8. Higuchi CM, Thompson JA. Petersen FB et al. Toxicity and immunomodulatory effects of interleukin 2 after autologous bone marrow transplantation for hematologic malignancies, Blood 1991; 77: 2261 (abstr.).
9. Stewart P, Buckner C, Bensinger W et al. Autologous marrow transplantation in patients with acute nonlymphocytic leukemia in first remission. Exp Hematol 1985; 13: 267-272.
10. Martin P. T cell depletion with antibodies: the Seattle experience. Bone Marrow Transplant 1987; 2: 53-57.
11. Lerner K, Kao G. Storb R et al. Histopathology of graft-vs-host reaction (GvHR) in human recipients of marrow from HL-A-matched sibling donors. Transplant Proc 1974; 6: 367-371.
12. Sale G, Lerner K, Barker E et al. The skin biopsy in the diagnosis of acute graft-versus-host disease in man. Am J Pathol 1977: 89: 621-636.
13. Sale GE, Beauchamp M, Myerson D. Immunohistologic staining of cytotoxic T- and NIC-cells in formalin-fixed paraffinembedded tissue using microwave TIA-1 antigen retrieval. Transplantation 1994; 57: 287-289.
14. Benyunes MC, Fefer A. IL-2 in the treatment of hematologic malignancies. In: Atkins MB and Mier JW (eds). Therapeutic Applications of Interleukin 2. Marcel Dekker: New York, 1993.
15. Benyunes M, York A, Lindgren C et al. IL-2 ± LAK cells as consolidative therapy after autologous BMT for hematologic malignancies: a feasibility trial. 1992. Proc Amer Soc Clin Oncol 1992, 11: 319 (abstr.).
16. Jakic-Razumovic J, Browne M, Sale G. Proliferation rates in epidermis of patients with graft-versus-host disease, non-specific inflammation and normal skin. Bone Marrow Transplant 1992; 10: 27-31.
17. Gaspari AA, Lotze MT, Rosenberg SA et al. Dermatologic changes associated with Interleukin 2 administration. JAMA 1987; 258: 1624-1629.
18. Sviland L, Pearson ADJ, Eastham EJ et al. Histological features of skin and rectal biopsy specimens after autologous and allogeneic bone marrow transplantation. J Clin Pathol 1988; 1: 148-154.
19. Sviland L, Pearson ADJ. Green MA et al. Expression of MHC class I and II antigens by keratinocytes and enterocytes in acute graft-versus-host disease. Bone Marrow Transplant 1989; 4: 233-238.
20. Jakic-Razumovic J, Sale GE, Beauchamp M et al. CD8+ activated T lymphocytes produce an in vitro skin graft-versus-host reaction in an organotypic skin culture model. Transplantation (in press).
21. Paller AS, Nelson A, Steffen L et al. T-lympyhocyte subsets in the lesional skin of allogeneic and autologous bone marrow transplant patients. Arch Dermatol 1988; 124: 1795-1801.
22. Oblakowski P, Bello-Fernandez C, Reittie J et al. Possible mechanism of selective killing of myeloid leukemic blast cells by lymphokine-activated killer cells. Blood 1991; 77: 1996-2001.
23. Cotran R, Pober J. Gimbrone J Jr et al. Endothelial activation during interleukin 2 immunotherapy: a possible mechanism for the vascular leak syndrome. J Immunol 1988; 140: 1883-1888.
24. Hess A, Horwitz L, Beschorner W et al. Development of graft-vs-host disease-like syndrome in cyclosporine-treated rats after syngeneic bone marrow transplantation. I. Development of cytotoxic T lymphocytes with apparent polyclonal anti-Ia specificity, meluding autoreactivity. J Exp Med 1985; 161: 718-730
25. Geller R, Esa A, Beschorner W et al. Successful in vitro graft-versus-tumor effect against an Ia-bearing tumor using cyclosporine-induced syngeneic graft-versus-host disease in the rat. Blood 1989; 74: 1165-1171.
26. Kennedy M. Beveridge R, Vogelsang G et al Phase I study of cyclosporin A (CsA) to induce graft-versus host disease (GVHD) following high-dose chemotherapy (HDC) with autologous marrow reinfusion (AMR) for metastatic breast cancer (MBC). Proc ASCO 1991: 10: 43 (abstract no. 48)
27. Jones R, Vogelsang G, Hess A et al. Induction of graft-versus-host disease after autologous bone marrow transplantation. Lancet 1989; i: 754-757.
28. Yeager A, Vogelsang G. Jones R et al. Induction of cutaneous graft-versus-host disease by administration of cyclosporine to patients undergoing autologous bone marrow transplantation for acute myeloid leukemia. Blood 1992; 79: 3031-3035.
29. Petersen F, Appelbaum F. Hill R et al. Autologous marrow transplantation for malignant lymphoma: a report of 101 cases from Seattle. J Clin Oncol 1990; 8: 638-647.
30. Benyunes M, Massumoto C, Higuchi C et al. Interleukin-2 ± lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia: a preliminary report. Bone Marrow Transplant 1993; 12: 159-163.
31. Fefer A, Benyunes M, Massumoto C et al. Interleukin-2 therapy after autologous bone marrow transplantation for hematological malignancies. Semin Oncol 1993; 20: 41-45.